Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy-MedSci.cn

Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy

Park, W; O'Connor, C; Chou, JF; Schwartz, C; Varghese, AM; Larsen, M; Balogun, F; Brenner, R; Yu, KH; Diguglielmo, E; Umeda, S; Karnoub, E; Keane, F; Zhang, H; Joshi, SS; Riaz, N; Kelsen, DP; Capanu, M; Iacobuzio-Donahue, CA; O'Reilly, EM

JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (16):

科室
- - 订阅+
  - 更多科室
工具
服务